Galapagos' affiliate BioFocus extends collaboration with Chiesi
(Thomson Reuters ONE) -
Mechelen, Belgium and Saffron Walden, UK; 14 October 2010 - Galapagos NV
(Euronext: GLPG) announced today that its BioFocus service division has expanded
a collaboration with Chiesi Farmaceutici, a privately held Italian
pharmaceutical company. Total value for the collaboration with Chiesi has now
reached ?2.5 million.
BioFocus and Chiesi began their collaboration in December 2009 and recently
extended it for one year. Under the terms of the extended collaboration
agreement, BioFocus will provide medicinal chemistry and biology services, with
an additional option for ADME services, for an undisclosed Chiesi therapeutic
program.
"BioFocus has a high return business rate with clients, and we are pleased that
Chiesi has chosen to extend this successful collaboration," said Onno van de
Stolpe, CEO of Galapagos. "The quality of the science at BioFocus enables it to
sustain its position as a premier provider in drug discovery services."
"The medicinal chemistry and biology work performed by BioFocus so far helped
us to accelerate progress on our therapeutic programs. We look forward to
working with BioFocus to move these programs forward toward the clinic," said Dr
Paolo Chiesi, R&D Director and Vice-President of Chiesi Farmaceutici.
About Chiesi Farmaceutici
With over 3,500 employees around the world, the Chiesi Group produces and
distributes successful drugs in 65 countries, and is present on 5 continents
with 24 direct affiliates, 4 research centres, and 3 production sites.
Respiratory pathologies, special care medicine, and cardiovascular disease are
its traditional areas of expertise where it offers many therapeutic options
recognized for their effectiveness. More info at:www.chiesigroup.com
About BioFocus
BioFocusaims to expand its partners' drug pipelines by accelerating the gene-to-
drug candidate discovery process. This is achieved through a comprehensive
discovery platform, which includes target discovery in human primary cells,
focused as well as diverse compound libraries, in vitro and cell-based
screening, structural biology, medicinal chemistry, ADME/PK services, supported
by unique chemogenomic and informatics tools, and compound library acquisition,
storage and distribution services. As a service division of Galapagos, BioFocus
has over 250 employees in four countries worldwide. More info at:
www.biofocus.com
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company
specialized in the discovery and development of small molecule and antibody
therapies with novel modes-of-action. The Company is progressing one of the
largest pipelines in biotech, with six clinical and over 50 small molecule
discovery/pre-clinical programs. Through risk/reward-sharing alliances with
GlaxoSmithKline, Lilly, Janssen Pharmaceutica, Merck & Co., Roche and Servier,
Galapagos is eligible to receive up to ?3.3 billion in downstream milestones,
plus royalties. Following the acquisition of the Zagreb research center, the
Galapagos Group now has over 800 employees and operates facilities in seven
countries, with global headquarters in Mechelen, Belgium. More info
at:www.glpg.com
CONTACTS
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir(at)glpg.com
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir(at)glpg.com
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
[HUG#1451788]
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 14.10.2010 - 07:30 Uhr
Sprache: Deutsch
News-ID 45513
Anzahl Zeichen: 0
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 193 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos' affiliate BioFocus extends collaboration with Chiesi"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
